A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis.

Abstract

A 2-year prophylactic trial was carried out in 31 bipolar manic-depressive subjects, comparing 300 mg/day methylene blue on a double-blind crossover basis with 15 mg/day. All patients were also maintained on lithium. Seventeen patients completed the 2-year trial. During the year the patients were treated with methylene blue at 300 mg/day, they were significantly less depressed than during the year on 15 mg/day. No significant difference in the severity of manic symptoms was shown. The trial had obvious limitations, e.g., a small number of subjects, a relatively large number of dropouts, relatively simple rating scales, doubts about blindness, and uncertainty as to whether or not 15 mg methylene blue per day could be considered a placebo. However, the results suggest that methylene blue may be a useful addition to lithium in the long-term treatment of manic-depressive psychosis and warrants further investigation.

050100'94'97'00'03'06'09'12'15
Citations per Year

345 Citations

Semantic Scholar estimates that this publication has 345 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Naylor1986ATD, title={A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis.}, author={Guy J Naylor and Brice Martin and Stephen Hopwood and Yvonne Watson}, journal={Biological psychiatry}, year={1986}, volume={21 10}, pages={915-20} }